[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Hansoh Biomedical Co., Ltd\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,39],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":4},"100597816","phase-1-phase-1-study-of-hs-20093-combinations-in-patients-with-extensive-stage-small-cell-lung-cancer-100597816",false,"NCT07063407","Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer","A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible for participation in this study:\n\n1. Men or women aged more than or equal to (≥) 18 years.\n2. Pathologically diagnosed as ES-SCLC.\n3. Without disease progression after receiving first-line standard induction therapy (Platinum + Etoposide +PD- (L) 1 inhibitor combination therapy).\n4. Eastern Cooperative Oncology Group (ECOG) performance status: 0\\~1.\n5. Estimated life expectancy \\>12 weeks.\n6. Adequate bone marrow reserve or serious organ dysfunction\n7. Reproductive-age women agree to use adequate contraception and cannot breastfeed while participating in this study and for a period of 6 months after the last dose. Likewise, men also consent to use adequate contraceptive method within the same time limit.\n8. Females must have evidence of non-childbearing potential.\n9. Signed and dated Informed Consent Form.\n\nExclusion Criteria:\n\n1. Uncontrolled pleural effusion or ascites or pericardial effusion.\n2. Known and untreated, or active central nervous system metastases.\n3. Active autoimmune diseases or active infectious disease\n4. Known to have interstitial pneumonia or immune pneumonia\n5. History of severe allergic reaction, serious transfusion reactions or Allergy to any component of HS-20093\n6. The subject who is unlikely to comply with study procedures, restrictions, or requirements judged by the investigator.\n7. The subject whose safety cannot be ensured or study assessments would be interfered judged by the investigator.\n8. Pregnant women, breastfeeding women or woman who has a child-bearing plan during the study.\n9. History of neuropathy or mental disorders, including epilepsy and dementia.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","This is a Phase I clinical study of HS-20093. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of HS-20093 in combination with Adebrelimab in patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC).",[26],"Extensive Stage Small Cell Lung Cancer (ES-SCLC)","NOT_YET_RECRUITING","2025-07-03",{"date":30,"type":31},"2025-07-14","ACTUAL",{"date":33,"type":20},"2025-07-31",{"date":35,"type":20},"2027-05-31",{"name":37,"class":38},"Shanghai Hansoh Biomedical Co., Ltd","INDUSTRY",{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":21,"phases":48,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100459504","phase-1-a-study-of-hs-20089-in-patients-with-advanced-solid-tumors-100459504","NCT05263479","A Study of HS-20089 in Patients With Advanced Solid Tumors","A Phase I, Open-label, Multicenter Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of HS-20089 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Men or women aged more than or equal to (≥) 18 years\n2. Advanced solid tumor patients confirmed by histology or cytology for who that standard treatment is invalid, unavailable or intolerable\n3. Patients have at least one target lesion according to RECEST 1.1. The requirements for target lesions are: measurable lesions without local treatment such as irradiation, or with definite progress after local treatment, with the longest diameter ≥ 10 mm in the baseline period (in case of lymph nodes, the shortest axis ≥ 15 mm is required)\n4. ECOG performance status was 0-1 and did not deteriorate in the previous 2 weeks\n5. Estimated life expectancy greater than (\\>) 12 weeks\n6. Females should be using adequate contraceptive measures throughout the study; should not be breastfeeding at the time of screening, during the study and until 3 months after completion of the study; and must have evidence of non-childbearing potential\n7. Sign Informed Consent Form\n\nExclusion Criteria:\n\n1. Treatment with any of the following:\n\n   1. Previous or current treatment with drugs targeting B7-H4\n   2. Any cytotoxic chemotherapy, investigational agents or anticancer drugs within 28 days of the first dose of study drug\n   3. Radiotherapy with a limited field of radiation for palliation within 2 weeks of the first dose of study drug, or patients received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 4 weeks of the first dose.\n   4. Major surgery (including craniotomy, thoracotomy, or laparotomy, etc.) within 4 weeks of the first dose of study drug.\n   5. Known and untreated, or active central nervous system metastases.\n2. Existing abnormal CTCAE≥grade 2 resulted from previous treatment\n3. History of other malignancy\n4. Inadequate bone marrow reserve or organ function\n5. Evidence of hepatitis B virus (HBV) or hepatitis C virus (HCV), unless the hepatitis is considered to be cured, Known history of HIV\n6. History of hypersensitivity to any active or inactive ingredient of HS-20089.\n7. Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements.\n8. Any disease or condition that, in the opinion of the investigator, would compromise the safety of the patient or interfere with study assessments.",{"count":47,"type":20},177,[23],"HS-20089 is a novel DAR-6 antibody-drug conjugate （ADC） targeting B7-H4. In preclinical studies, it inhibited tumor cell growth expressing B7-H4 in vitro and in vivo. The first-in-human trial is conducted to assess the maximum tolerated dose (MTD) and dose limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HS-20089 in Patients With Advanced Solid Tumors.",[51],"Advanced Solid Tumor",[53,54,55,51],"HS-20089","ADC","B7-H4","RECRUITING","2024-04-01",{"date":59,"type":31},"2024-04-03",{"date":61,"type":31},"2022-01-05",{"date":63,"type":20},"2026-12-31",{"name":37,"class":38},1,""]